PDE9 Inhibition with CRD-740 Safely Elevates cGMP Levels in HFrEF: Results from the CARDINAL-HF Trial

Highlights

The primary findings of the CARDINAL-HF trial underscore the therapeutic potential of PDE9 inhibition in heart failure management. Key takeaways include:

• CRD-740 significantly increased plasma cGMP levels compared to placebo, with a least squared mean difference of 26.5%.
• The pharmacodynamic effect was additive to standard-of-care treatments, including sacubitril/valsartan (ARNI therapy).
• Urinary cGMP levels also showed significant increases at multiple time points, suggesting systemic enhancement of the natriuretic peptide pathway.
• The drug demonstrated a favorable safety profile with no significant impact on systolic blood pressure or increased rates of hypotension.